Tarsus Pharmaceuticals, Inc.
TARS
Peringkat dalam Saham
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$71.12
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$3.33B
Perubahan (1 hari)
2.33%
Perubahan (1 tahun)
0.42%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Riwayat pemecahan saham untuk Tarsus Pharmaceuticals, Inc. (TARS)
Saham Tarsus Pharmaceuticals, Inc. (simbol: TARS) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham TARS yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham TARS.
Pemecahan saham terbaru terjadi pada Oct 21, 2026.
Satu lembar saham TARS yang dibeli sebelum Oct 21, 2026 sekarang setara dengan 0 lembar saham TARS.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
